Other author/creator | Hanson, Sarah L. (Sarah Lynn), 1980- |
Other author/creator | Davis, Miriam (Medical writer) |
Other author/creator | Altevogt, Bruce M. |
Other author/creator | Institute of Medicine (U.S.). Forum on Neuroscience and Nervous System Disorders. |
Other author/creator | National Academies Press (U.S.) |
Variant title |
Central nervous system clinical trials |
Contents |
Perspectives from the FDA, academia, and patients -- Data collection and optimization -- Data analysis -- Partnerships, opportunities, collaboration. |
Abstract |
"The Food and Drug Administration (FDA) now requires that all clinical trials for drugs that affect the central nervous system--including psychiatric drugs--are assessed for whether that drug might cause suicidal ideation or behavior. The Institute of Medicine's (IOM) Forum on Neuroscience and Nervous System Disorders hosted a meeting on June 26, 2009, to discuss the FDA's new policy and how to analyze best whether suicidal thoughts predict actual suicidal behavior in the near future."--Publisher's description. |
Bibliography note | Includes bibliographical references (p. 43-49). |
Access restriction | Available only to authorized users. |
Other forms | Also issued online. |
Technical details | Mode of access: World Wide Web |
Genre/form | Electronic books. |
LCCN | 2012419234 |
ISBN | 9780309148832 (pbk.) |
ISBN | 0309148839 (pbk.) |